Vical Incorporated To Present At The Leerink Global Healthcare Conference

SAN DIEGO, Feb. 9, 2015 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) today announced that the company will participate in a fireside chat discussion at the Leerink Global Healthcare Conference in New York. The discussion is scheduled for Wednesday, February 11th at 2:15 p.m. Eastern Time. A webcast of the company’s discussion will be available live and archived through the Events & Presentations page in the Investors section of the Vical website at www.vical.com.

About Vical

Vical researches and develops biopharmaceutical products leveraging its patented DNA delivery technologies for the prevention and treatment of chronic or life-threatening infectious diseases. In addition, the company has collaborations with major pharmaceutical and biotechnology companies focused on addressing significant unmet medical needs. Additional information on Vical is available at www.vical.com.

This press release contains forward-looking statements subject to risks and uncertainties that could cause actual results to differ materially from those projected. Forward-looking statements include statements about the company’s focus, collaborative partners, product candidates, and developmental status. Risks and uncertainties include whether any product candidates will be shown to be safe and efficacious in clinical trials, the timing of clinical trials, whether Vical or its collaborative partners will seek or gain approval to market any product candidates, the dependence of the company on its collaborative partners, and additional risks set forth in the company’s filings with the Securities and Exchange Commission. These forward-looking statements represent the company’s judgment as of the date of this release. The company disclaims, however, any intent or obligation to update these forward-looking statements.

CONTACT: Andrew Hopkins (858) 646-1127 Website: www.vical.com

Vical Logo


Help employers find you! Check out all the jobs and post your resume.

MORE ON THIS TOPIC